The inhibition of Drp1 not only corrects glycolytic deficits in mature OLs but also reduces NLRP3 inflammasome activation, alleviates myelin and axonal loss, and improves cognitive function in AD mouse models [45]. The gene discussed is DNM1L; the disease is Alzheimer disease.